Some new insights in intestinal failure-associated liver disease

Current Opinion in Organ Transplantation

Volumn 14, Issue 3, 2009, Pages 256-261

  Goulet, Olivier ^a   Joly, Francisca ^a   Corriol, Odile ^a   Colomb Jung, Virginie ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Essential fatty acids; Intestinal failure associated liver disease; Intravenous lipid emulsion; Parenteral nutrition; Phytosterol; Tocopherol

Indexed keywords

ALPHA TOCOPHEROL; FISH OIL; INTRALIPID; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OMEGAVEN; PHYTOSTEROL; SMOFLIPID; SOYBEAN OIL EMULSION; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; LIPID EMULSION; SOYBEAN OIL;

ANTIOXIDANT ACTIVITY; CHOLESTASIS; DISEASE ASSOCIATION; ENTEROPATHY; FAT INTAKE; HUMAN; INTESTINE FAILURE; INTESTINE FAILURE ASSOCIATED LIVER DISEASE; INTESTINE MOTILITY; LIVER DISEASE; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SHORT BOWEL SYNDROME; VITAMIN INTAKE; INFANT; LIVER TRANSPLANTATION; NEWBORN; TOTAL PARENTERAL NUTRITION;

CHOLESTASIS; FAT EMULSIONS, INTRAVENOUS; FISH OILS; HUMANS; INFANT; INFANT, NEWBORN; INTESTINAL DISEASES; LIVER DISEASES; LIVER TRANSPLANTATION; PARENTERAL NUTRITION, TOTAL; RISK FACTORS; SHORT BOWEL SYNDROME; SOYBEAN OIL;

EID: 67651019004     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832ac06f     Document Type: Review

References (66)

1. Goulet O, Ruemmele F. Causes and management of intestinal failure in children. Gastroenterology 2006; 130:S16-S28. (Pubitemid 43208856)
2. Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in neonates with intestinal resection and long term parenteral nutrition. J Pediatr Gastroenterol Nutr 1998; 6:131-137. (Pubitemid 28354942)
3. Nightingale JM. Hepatobiliary, renal and bone complications of intestinal failure. Best Pract Res Clin Gastroenterol 2003; 17:907-929. (Pubitemid 38001808)
4. Vina J, Vento M, Garcia-Sala F, et al. L-cysteine and glutathione metabolism are impaired in premature infants due to cystathionase deficiency. Am J Clin Nutr 1995; 61:1067-1069.
5. Kaufman SS. Prevention of parenteral nutrition-associated liver disease in children. Pediatr Transplant 2002; 6:37-42. (Pubitemid 34269734)
6. Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin Gastroenterol 2003; 19:216-231.
7. Teitelbaum DH, Tracy T. Parenteral nutrition-associated cholestasis. Semin Pediatr Surg 2001; 10:72-80.
8. Buchman AL, Iyer K, Fryer J. Parenteral nutrition-associated liver disease and the role of isolated intestine and intestine/liver transplantation. Hepatology 2006; 43:9-19. (Pubitemid 43733585)
9. Gura KM, Parsons SK, Bechard LJ, et al. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr 2005; 24:839-847.
10. Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006; 118:e197-e201.
11. Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121:e678-e686. The authors compared safety and efficacy outcomes of a fish oil-based fat emulsion in 18 infants with SBS who developed cholestasis (serum direct bilirubin level > 2 mg/dl) while receiving soybean emulsions with those from a historical cohort of 21 SBS infants who also developed cholestasis while receiving soybean emulsions. The main results observed among survivors is that the median time to reversal of cholestasis was 9.4 and 44.1 weeks in the fish oil-based fat emulsion and historical cohorts, respectively. Potential mechanisms of the dramatic effects of fish oil-based fat emulsion are discussed with regard to n-3:n-6 FAs ratio, phytosterols but they did not discuss the beneficial effects of a-toc neither EFA status in patients receiving long-term fish oil-based fat emulsion.
12. Wales PW, Diamond IR, Sterescu A, et al. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. 39th Annual meeting of the Canadian Association of Pediatric Surgeons. St Johns, Newfoundland; 2007.
13. Ekema G, Falchetti D, Boroni G, et al. Reversal of severe parenteral nutrition-associated liver disease in an infant with short bowel syndrome using parenteral fish oil (omega-3 fatty acids). J Pediatr Surg 2008; 43:1191-1195. (Pubitemid 351814874)
14. Zaman N, Tam YK, Jewell LD, Coutts RT. Effects of intravenous lipid as a source of energy in parenteral nutrition associated hepatic dysfunction and lidocaine elimination: a study using isolated rat liver perfusion. Biopharm Drug Dispos 1997; 18:803-819. (Pubitemid 27517569)
15. Beckh K, Kneip S, Arnold R. Direct regulation of bile secretion by prostaglandins in perfused rat liver. Hepatology 1994; 19:1208-1213. (Pubitemid 24134243)
16. Furst P, Kuhn KS. Fish oil emulsions: what benefits can they bring? Clin Nutr 2000; 19:7-14.
17. Steephen AC, Traber MG, Ito Y, et al. Vitamin E status of patients receiving long-term parenteral nutrition: is vitamin E supplementation adequate? J Parenter Enteral Nutr 1991; 15:647-652.
18. Traber MG, Carpentier YA, Kayden HJ, et al. Alterations in plasma alpha- and gammatocopherol concentrations in response to intravenous infusion of lipid emulsions in humans. Metabolism 1993; 42:701-709.
19. Steger PJ, Muhlebach SF. Lipid peroxidation of i.v. lipid emulsions in TPN bags: the influence of tocopherols. Nutrition 1998; 14:179-185.
20. Van Gossum A, Shariff R, Lemoyne M, et al. Increased lipid peroxidation after lipid infusion as measured by breath pentane output. Am J Clin Nutr 1988; 48:1394-1399. (Pubitemid 19008570)
21. Lemoyne M, Van Gossum A, Kurian R, Jeejeebhoy KN. Plasma vitamin E and selenium and breath pentane in home parenteral nutrition patients. Am J Clin Nutr 1988; 48:1310-1315. (Pubitemid 18271945)
22. Wanten G, Beunk J, Naber A, Swinkels D. Tocopherol isoforms in parenteral lipid emulsions and neutrophil activation. Clin Nutr 2002; 21:417-422. (Pubitemid 35189952)
23. Dupont IE. Peroxidation of lipid emulsions: effects of changes in fatty acid pattern and alpha-tocopherol content on the sensitivity to peroxidative damage. Clin Nutr 1999; 18:113-116.
24. Linseisen J, Hoffmann J, Lienhard S, et al. Antioxidant status of surgical patients receiving TPN with an omega-3-fatty acid-containing lipid emulsion supplemented with alpha-tocopherol. Clin Nutr 2000; 19:177-184. (Pubitemid 30599308)
25. Manuel-y-Keenoy B, Nonneman L, De Bosscher H, et al. Effects of intravenous supplementation with alpha-tocopherol in patients receiving total parenteral nutrition containing medium- and long-chain triglycerides. Eur J Clin Nutr 2002; 56:121-128. (Pubitemid 34145154)
26. Clayton PT, Bowron A, Mills KA, et al. Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology 1993; 105:1806-1813. (Pubitemid 24002799)
27. Iyer KR, Spitz L, Clayton P. BAPS prize lecture: new insight into mechanisms of parenteral nutrition-associated cholestasis - role of plant sterols. British Association of Paediatric Surgeons. J Pediatr Surg 1998; 33:1-6.
28. Carter BA, Prendergast DR, Taylor OA, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res 2007; 62:301-306.
29. Carter BA, Shulman RJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol 2007; 4:277-287.
30. Goulet O, Postaire M, De Potter S, et al. Medium-chain triglycerides and long-chain parenteral nutrition in children. Nutrition 1992; 8:333-337.
31. Goulet O, de Potter S, Antébi H, et al. Long-term efficacy and safety of a new olive oil-based intravenous fat emulsion in pediatric patients: a double-blind randomized study. Am J Clin Nutr 1999; 70:338-345. (Pubitemid 29407153)
32. Göbel Y, Koletzko B, Böhles HJ, et al. Parenteral fat emulsions based on olive and soybean oils: a randomized clinical trial in preterm infants. J Pediatr Gastroenterol Nutr 2003; 37:161-167.
33. Colomb V, Jobert-Giraud A, Lacaille F, et al. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. J Parenter Enteral Nutr 2000; 24:345-350. (Pubitemid 30805262)
34. Krohn K, Koletzko B. Parenteral lipid emulsions in paediatrics. Curr Opin Clin Nutr Metab Care 2006; 9:319-323.
35. Adolph M. Lipid emulsions in parenteral nutrition. Ann Nutr Metab 1999; 43:1-13.
36. Waitzberg DL, Torrinhas RS, Jacintho TM. New parenteral lipid emulsions for clinical use. J Parenter Enteral Nutr 2006; 30:351-367.
37. Elmadfa I, Bosse W. Vitamin E demand. In: Elmadfa I, Bosse W, editors. Vitamin E: Quality, effect and therapeutic importance (in German). Stuttgart: Wissenschaftliche Verlagsgesellschft mbH;1985.
38. Mayer K, Schaefer MB, Seeger W. Fish oil in the critically ill: from experimental to clinical data. Curr Opin Clin Nutr Metab 2006; 9:140-148. (Pubitemid 44090038)
39. Mertes N, Grimm H, Fürst P, Stehle P. Safety and efficacy of a new parenteral lipid emulsion (SMOFlipid) in surgical patients: a randomized, double-blind, multicenter study. Ann Nutr Metab 2006; 50:253-259. (Pubitemid 43829816)
40. Schlotzer E, Kanning U. Elimination and tolerance of a new parenteral lipid emulsion (SMOF): a double-blind cross-over study in healthy male volunteers. Ann Nutr Metab 2004; 48:263-268. (Pubitemid 39382386)
41. Antébi H, Mansoor O, Ferrier C, et al. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions. J Parenter Enteral Nutr 2004; 28:142-148. (Pubitemid 38507242)
42. Genton L, Karsegard VL, Dupertuis YM, et al. Tolerance to a lipid emulsion containing a mixture of soybean, olive, coconut and fish oil compared with a standard fat emulsion containing only soybean oil. Clin Nutr 2004; 23:793.
43. Grimm H, Mertes N, Goeters C, et al. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur J Nutr 2006; 45:55-60. (Pubitemid 43221285)
44. Tomsits E, Pataki M, Tölgyesi A, et al. Evaluation of the safety and tolerability of SMOF lipid 20% compared to Intralipid 20% in parenteral nutrition of premature babies. Pediatr Crit Care Med 2007; 8 (Suppl):A247.
45. Rayyan M, Allegaert K, Devlieger H. Effect of a new type of lipid emulsion based on soybean oil, MCT, olive oil, and fish oil (SMOF20%) in preterm infants. Pediatr Crit Care Med 2007; 8 (Suppl):A318.
46. Goulet O, Antebi H, Wolf C, et al. A new intravenous fat emulsion containing fish oil: a single center, double-blind randomized study on long-term efficacy and safety in pediatric patients. J Parenter Enteral Nutr 2009 (in press).
47. Kaufman SS, Loseke CA, Lupo JV, et al. Influence of bacterial overgrowth and intestinal inflammation on duration of PN in children with short bowel syndrome. J Pediatr 1997; 131:356-361.
48. Jones A, Selby PJ, Viner C, et al. Tumour necrosis factor, cholestatic jaundice, and chronic liver disease. Gut 1990; 31:938-939. (Pubitemid 20269548)
49. Fryer J, Pellar S, Ormond D, et al. Mortality in candidates waiting for combined liver-intestine transplants exceeds that for other candidates waiting for liver transplants. Liver Transpl 2003; 9:748-753. (Pubitemid 36874465)
50. Freeman RB Jr, Steffick DE, Guidinger MK, et al. Liver and intestine transplantation in the United States. Am J Transplant 2008; 8:958-976.
51. Diamanti A, Basso MS, Castro M, et al. Irreversible intestinal failure: prevalence and prognostic factors. J Pediatr Gastroenterol Nutr 2008; 47:450-457. In this series of patients with intestinal failure, survival rate was significantly higher in SBS patients than in the other groups (P < 0.01). SBS patients showed a higher rate of major complications, though only IFALD was significantly higher (P < 0.001).
52. Putchakayala K, Polensky S, Fitzhugh J, et al. An evaluation of model for endstage liver disease and serum C-reactive protein as prognostic markers in intestinal failure patients on PN. J Parenter Enteral Nutr 2009; 33:55-61. The authors evaluated for the first time the use of the model for end-stage liver disease (MELD) and serum C-reactive protein (CRP) as predictive markers of mortality in intestinal failure patients. Both seem to be promising clinical tools to identify which patients are at highest risk for complication.
53. Mian SI, Dutta S, Le B, et al. Factors affecting survival to intestinal transplantation in the very young pediatric patient. Transplantation 2008; 85:1287-1289. In children younger than 18 months, risk factors affecting survival to intestinal transplantation include small body size and advanced liver disease. A primary diagnosis of intestinal atresia and the presence of the ileocecal valve may confer additional risk to these very young children.
54. Pironi L, Forbes A, Joly F, et al., Home Artificial Nutrition Working Group of the European Society for Clinical Nutrition and Metabolism (ESPEN) Collaborators. Survival of patients identified as candidates for intestinal transplantation: a 3-year prospective follow-up. Gastroenterology 2008; 135:61-71.
55. Grant D, Abu-Elmagd K, Reyes J, et al., Intestine Transplant Registry. 2003 report of the intestine transplant registry: a new era has dawned. Ann Surg 2005; 241:607-613.
56. Lacaille F, Vass N, Sauvat F, et al. Long-term outcome, growth and digestive function in children 2 to 18 years after intestinal transplantation. Gut 2008; 57:455-461. This series of 31 children indicates that long-term intestinal autonomy for up to 18 years is possible in the majority of patients after intestinal Tx. Subnormal energy absorption and moderate steatorrhea were often compensated for by hyperphagia, allowing normal growth and attainment of adult height. Long-term compliance is an important prerequisite for long-term graft function.
57. Botha JF, Grant WJ, Torres C, et al. Isolated liver transplantation in infants with end-stage liver disease due to short bowel syndrome. Liver Transpl 2006; 12:1062-1066. (Pubitemid 44063779)
58. Reinshagen K, Zahn K, Buch C, et al. The impact of longitudinal intestinal lengthening and tailoring (LILT) on liver function in short bowel syndrome. Eur J Pediatr Surg 2008; 18:249-253. The authors reported a cohort of 55 patients with SBS managed with LILT. After LILT, all patients with liver fibrosis who could be weaned from parenteral nutrition showed a normalization of liver enzymes. They consider that preoperative liver biopsy is mandatory in order to differentiate reversible liver fibrosis from end-stage liver disease.
59. Modi BP, Javid PJ, Jaksic T, et al., International STEP Data Registry. First report of the international serial transverse enteroplasty data registry: indications, efficacy, and complications. J Am Coll Surg 2007; 204:365-367. This is the first report of the International STEP Data Registry including the first 38 patients in 19 centers from three countries. Median follow-up was of 12.6 months (range 0-66.9 months). Mean small intestine length was substantially increased (68 ± 44 cm versus 115 ± 87 cm, P < 0.0001, n = 27). Late outcomes included progression to transplantation (n = 3) and mortality (n = 3). For the SBS cohort, enteral tolerance was notably increased from 31 ± 31% to 67 ± 37% of calories (P < 0.01, n = 21).
60. Andres AM, Thompson J, Grant W, et al. Repeat surgical bowel lengthening with the STEP procedure. Transplantation 2008; 85:1294-1299. Repeat lengthening with STEP was performed 16 times in 14 patients leading to discontinuation of TPN in almost half of these carefully selected patients and does not preclude intestinal transplantation. (Pubitemid 351670480)
61. Fiel MI, Sauter B, Wu HS, et al. Regression of hepatic fibrosis after intestinal transplantation in total parenteral nutrition liver disease. Clin Gastroenterol Hepatol 2008; 6:926-933. From four patients who underwent isolated intestinal transplantation having significant liver fibrosis, the authors consider that significant hepatic fibrosis and liver dysfunction may regress after intestinal transplantation and fibrosis regresses more rapidly in portal areas. This suggests that some patients with IFALD may safely undergo isolated intestinal transplant without the need for concurrent liver transplantation and its attendant higher morbidity and mortality.
62. Salvia G, Guarino A, Terrin G, et al., Working Group on Neonatal Gastroenterology of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition. Neonatal onset intestinal failure: an Italian Multicenter Study. J Pediatr 2008; 153:674-676.
63. Lloyd DA, Zabron AA, Gabe SM. Chronic biochemical cholestasis in patients receiving home parenteral nutrition: prevalence and predisposing factors. Aliment Pharmacol Ther 2008; 27:552-560. This study shows that chronic biochemical cholestasis is common in patients receiving home parenteral nutrition. By multivariate analysis, it shows that high parenteral calorie intake and lack of a colon in continuity with small intestine are independently associated with an increased risk of chronic biochemical cholestasis.
64. Lopushinsky SR, Fowler RA, Kulkarni GS, et al. The optimal timing of intestinal transplantation for children with intestinal failure: a Markov analysis. Ann Surg 2007; 246:1092-1099. A Markov analytic model was used to determine life expectancy and quality-adjusted life years on a theoretical cohort of 4-year-old patients for two treatment strategies: standard care consisting of parenteral nutrition and referral to transplantation according to accepted guidelines and early listing for isolated small intestine transplantation. Children with SBS dependent on parenteral nutrition should be considered for intestinal transplantation earlier than what is current practice.
65. Racine RA, Deckelbaum RJ. Sources of the very-long-chain unsaturated omega-3 fatty acids: eicosapentaenoic acid and docosahexaenoic acid. Curr Opin Clin Nutr Metab Care 2007; 10:123-128.
66. Mayer K, Seeger W. Fish oil in critical illness. Curr Opin Clin Nutr Metab Care 2008; 11:121-127.